[Controlled study of the administration of CDP-choline to preterm newborn infants with respiratory distress syndrome]

An Esp Pediatr. 1988 Jun;28(6):493-6.
[Article in Spanish]

Abstract

A randomized prospective double-blind trial of CDP-Choline administration to a group of 24 preterm newborn infants with respiratory distress syndrome is reported. CDP-choline was administered by the intravenous route (100 mg/kg/day) for seven days, or until less than 30% supplemental oxygen was needed. By the fifth day of life, the patients who received CDP-choline required oxygen for a longer period of time, and had a lower lecithin/sphingomyelin ratio and palmitic acid percentage than those in the control group. At the dose given, CDP-choline did not induce postnatal pulmonary maturity. In fact, it may even decrease lecithin synthesis.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Choline / analogs & derivatives*
  • Cytidine Diphosphate Choline / therapeutic use*
  • Double-Blind Method
  • Humans
  • Infant, Newborn
  • Oxygen Inhalation Therapy
  • Palmitic Acid
  • Palmitic Acids / analysis
  • Phosphatidylcholines / analysis
  • Prospective Studies
  • Pulmonary Surfactants / analysis
  • Random Allocation
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / physiopathology
  • Sphingomyelins / analysis

Substances

  • Palmitic Acids
  • Phosphatidylcholines
  • Pulmonary Surfactants
  • Sphingomyelins
  • Palmitic Acid
  • Cytidine Diphosphate Choline
  • Choline